Modality treatment including surgery, chemotherapy, radiation and immunotherapy was considered as standard strategy for tonsillar squamous cell carcinoma (TSCC). We reported a case of a 78-year-old man under severe underlying medical conditions who diagnosed with human papillomavirus (HPV)-positive and programmed death ligand 1 (PD-L1)-positive TSCC. He was administered camrelizumab combined with gemcitabine (GEM) for 8 cycles with partial response. Then, we gave him concurrent nanoparticle albumin-bound paclitaxel (nab-paclitaxel)-based chemoradiation. Eventually, this patient achieved complete response without severe adverse events. After a 12-month follow-up, he had no recurrence or metastasis.
No clinical trial protocols linked to this paper
Clinical trials are automatically linked when NCT numbers are found in the paper's title or abstract.PICO Elements
No PICO elements extracted yet. Click "Extract PICO" to analyze this paper.
Paper Details
MeSH Terms
Associated Data
No associated datasets or code repositories found for this paper.
Related Papers
Related paper suggestions will be available in future updates.